July 21, 2026
Biotechnology group Alachua Government Services received confirmation Tuesday of its Chapter 11 plan from a Delaware bankruptcy judge after reaching an agreement to resolve a dispute over a $147 million claim from the U.S. Department of Defense.
June 10, 2026
Biotech group Alachua Government Services asked a Delaware bankruptcy judge to trim the U.S. Department of Defense's Chapter 11 claim by $142 million, saying the government relied upon inapplicable federal regulations in claims connected to rejected contracts.
June 04, 2026
A Delaware bankruptcy judge on Thursday agreed to conditionally approve the disclosure statement for biotechnology company Alachua Government Services' Chapter 11 liquidation plan after the debtor announced it had settled a long-running outstanding dispute.
June 02, 2026
The U.S. government has asked a Delaware bankruptcy judge to reject Alachua Government Services' disclosure statement for its liquidation plan, saying the biotechnology company is proposing to shortchange the Department of Defense's claims against the debtor.
February 09, 2026
Biotechnology company Alachua Government Services received approval on Monday from a Delaware bankruptcy judge for a $16 million sale to healthcare investment firm OrbiMed Advisors LLC of the royalty rights to a line of monkey cells being used to develop a smallpox vaccine.
January 21, 2026
Biotech company Alachua Government Services has won approval to enter into a $10.3 million stalking horse bid from Emergent Biosolutions Inc. for a line of monkey cells being used to develop a smallpox vaccine.
December 05, 2025
A Delaware bankruptcy judge Friday gave a Florida biotechnology company permission to hold an auction in January for the royalty rights to a line of monkey cells being used to develop a smallpox vaccine.